Biora Therapeutics, Inc. (BIORQ)
| Market Cap | 442.00 -100.0% |
| Revenue (ttm) | 892.00K +4,855.6% |
| Net Income | -31.54M |
| EPS | -10.46 |
| Shares Out | 4.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,002 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.3400 |
| Beta | 158.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Biora Therapeutics
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]
Financial Performance
In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.
Financial StatementsNews
Biora Therapeutics Quarterly report: Q3 2024
Biora Therapeutics has published its Q3 2024 quarterly earnings report on November 14, 2024.
Biora Therapeutics Earnings release: Q3 2024
Biora Therapeutics released its Q3 2024 earnings on November 14, 2024, summarizing the period's financial results.
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreemen...
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024
Biora Therapeutics Proxy statement: Proxy Filing
Biora Therapeutics filed a proxy statement on October 23, 2024, providing details for shareholder voting and corporate governance matters.
Biora Therapeutics Proxy statement: Proxy Filing
Biora Therapeutics filed a proxy statement on October 11, 2024, providing details for shareholder voting and corporate governance matters.
Biora Therapeutics Proxy statement: Proxy Filing
Biora Therapeutics filed a proxy statement on September 16, 2024, providing details for shareholder voting and corporate governance matters.
Biora Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference
Two innovative drug-device platforms were highlighted: NaviCap, which showed strong phase I results for targeted ulcerative colitis therapy, and BioJet, advancing needle-free biologic delivery with active pharma partnering discussions. Both programs are positioned for significant near-term milestones.
Biora Therapeutics Proxy statement: Proxy Filing
Biora Therapeutics filed a proxy statement on September 3, 2024, providing details for shareholder voting and corporate governance matters.
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in ...
Biora Therapeutics Registration statement: Registration Filing
Biora Therapeutics filed a registration statement on August 23, 2024, providing details about a securities offering with the SEC.
Biora Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Two proprietary platforms enable targeted and systemic oral drug delivery, with NaviCap showing strong phase I results in UC and BioJet advancing through major pharma collaborations. Next steps include a larger UC trial and anticipated BioJet partnerships.
Biora Therapeutics Earnings Call Transcript: Q2 2024
Q2 2024 saw successful Phase 1 results for BT-600, strong progress with BioJet, and a $16M capital raise. BioJet achieved ~40% bioavailability, and partnership talks with major pharma are nearing completion. Clinical trials and manufacturing scale-up are on track.
Biora Therapeutics Quarterly report: Q2 2024
Biora Therapeutics has published its Q2 2024 quarterly earnings report on August 12, 2024.
Biora Therapeutics Earnings release: Q2 2024
Biora Therapeutics released its Q2 2024 earnings on August 12, 2024, summarizing the period's financial results.
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan
Biora Therapeutics Announces Funding Agreement with Existing Investors
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its...
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...
Biora Therapeutics Transcript: Study Update
Phase I results for BT-600 using the NaviCap platform showed precise, pancolonic delivery of tofacitinib with significantly reduced systemic exposure and strong safety in healthy volunteers. These findings support further clinical development in ulcerative colitis patients.
Biora Therapeutics Press release: Study Update
Biora Therapeutics issued a press release on July 17, 2024, disclosing material business information to investors.
Biora Therapeutics Slides: Study Update
Biora Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2024.
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical dat...
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.